Multicenter Atrial fibrillation Intervention Keeps innOvating registry

JRCT ID: jRCT1050200005

Registered date:23/04/2020

Basic Information

• Recruitment status: Suspended
• Health condition(s) or Problem(s) studied: Atrial fibrillation
• Date of first enrollment: 08/01/2019
• Target sample size: 3000
• Study type: Observational

Outcome(s)

• Primary Outcome: Atrial tachyarrhythmias lasting for > 30 seconds or requiring repeat ablation, hospital admission, cardioversion or antiarrhythmic drug (AAD) therapy* between 91 and 365 days after ablation.

Secondary Outcome

1 Atrial tachyarrhythmias lasting for > 30 seconds or requiring repeat ablation, hospital admission, cardioversion or antiarrhythmic drug (AAD) therapy between 0 and 90 days after ablation.
2 Repeat Ablation for atrial tachyarrhythmias.
3 Atrial tachyarrhythmias lasting for > 30 seconds or requiring repeat ablation, hospital admission, cardioversion or AAD therapy after ablation.
4 Exacerbation of congestive heart failure (emergency admission or hospitalization)
5 Worsening renal function (reduction of eGFR >30%)
6 Stroke (Ischemic stroke and intracranial hemorrhage)
7 Quality of Life (QOL) score.
8:Biomarkers (TnI, CRP, CK, CKMB, NGAL, Cre, BNP, NT-pro BNP)

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

Patients undergoing catheter ablation including PV isolation for symptomatic atrial fibrillation
Patients who are over 20 years old
Willing to sign the consent form for participation

• Exclude criteria: None

Related Information

• Primary Sponsor: Kawaji Tetuma